Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

The growing incidence of infectious diseases, cancer, and chronic illnesses has substantially increased the demand for ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

By contrast, mRNA vaccines developed by Moderna and BioNTech had to be developed from scratch, and quickly. Moderna stated that it took the company 63 days to move from sequencing to human trials.